Silence of the transcripts: RNA interference in medicine

Journal of Molecular Medicine

Volumn 83, Issue 10, 2005, Pages 764-773

  Barik, Sailen ^a,b,c  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b Department of Biochemistry and Molecular Biology ^*  (United States)

^c UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Antiviral; Cancer; Infectious disease; RNA drug; RNA interference; siRNA

Indexed keywords

DOUBLE STRANDED RNA; MESSENGER RNA; RECOMBINANT INTERFERON; SMALL INTERFERING RNA;

CHROMATIN ASSEMBLY AND DISASSEMBLY; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENE THERAPY; GENETIC DISORDER; GENETIC REGULATION; MALIGNANT NEOPLASTIC DISEASE; MEDICINE; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NEUROLOGIC DISEASE; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; REVIEW; RNA DEGRADATION; RNA INTERFERENCE; RNA TRANSCRIPTION; RNA TRANSLATION; TRANSLATION REGULATION; VIRUS INFECTION;

ANIMALS; COMMUNICABLE DISEASES; GENETIC DISEASES, INBORN; HUMANS; INTERFERONS; METABOLIC DISEASES; MICE; MICRORNAS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 26044469804     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-005-0690-0     Document Type: Review

References (131)

1. Storz G (2002) An expanding universe of noncoding RNAs. Science 296:1260-1263
2. Lolle SJ, Victor JL, Young JM, Pruitt RE (2005) Genome-wide non-mendelian inheritance of extra-genomic information in Arabidopsis. Nature 434:505-509
3. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811
4. Romano N, Macino G (1992) Quelling: transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences. Mol Microbiol 6:3343-3353
5. van der Krol AR, Mur LA, Held M, Mol JN, Stuitje AR (1990) Flavonoid genes in petunia: addition of a limited number of gene copies may lead to a suppression of gene expression. Plant Cell 2:291-299
6. Napoli C, Lemieux C, Jorgensen R (1990) Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2:279-289
7. de Carvalho F, Gheysen G, Kushnir S, Van Montagu M, Inze D, Castresana C (1992) Suppression of beta-1,3-glucanase transgene expression in homozygous plants. EMBO J 11:2595-2602
8. Mello CC, Conte D Jr (2004) Revealing the world of RNA interference. Nature 431:338-342
9. Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431:343-349
10. Bhalla KN (2005) Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23:3971-3993
11. Carmell MA, Hannon GJ (2004) RNase III enzymes and the initiation of gene silencing. Nat Struct Mol Biol 11:214-218
12. Sontheimer EJ (2005) Assembly and function of RNA silencing complexes. Nat Rev Mol Cell Biol 6:127-138
13. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297
14. Ambros V (2004) The functions of animal microRNAs. Nature 431:350-355
15. Sledz CA, Williams BR (2004) RNA interference and double-stranded-RNA- activated pathways. Biochem Soc Trans 32:952-956
16. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, Hannon GJ (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science 305:1437-1441
17. Rand TA, Ginalski K, Grishin NV, Wang X (2004) Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc Natl Acad Sci U SA 101:14385-14389
18. Orban TI, Izaurralde E (2005) Decay of mRNAs targeted by RISC requires XRN1, the Ski complex, and the exosome. RNA 11:459-469
19. Rivas FV, Tolia NH, Song JJ, Aragon JP, Liu J, Hannon GJ, Joshua-Tor L (2005) Purified Argonaute2 and an siRNA form recombinant human RISC. Nat Struct Mol Biol 12:340-349
20. Lingel A, Simon B, Izaurralde E, Sattler M (2004) Nucleic acid 3′-end recognition by the Argonaute2 PAZ domain. Nat Struct Mol Biol 11:576-577
21. Song JJ, Smith SK, Hannon GJ, Joshua-Tor L (2004) Crystal structure of Argonaute and its implications for RISC sheer activity. Science 305:1434-1437
22. Parker JS, Roe SM, Barford D (2005) Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex. Nature 434:663-666
23. Ma JB, Yuan YR, Meister G, Pei Y, Tuschl T, Patel DJ (2005) Structural basis for 5′-end-specific recognition of guide RNA by the A. fulgidus Piwi protein. Nature 434:666-670
24. Ma JB, Ye K, Patel DJ (2004) Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature 429:318-322
25. Griffiths-Jones S (2004) The microRNA registry. Nucleic Acids Res 32:D109-D111
26. Heale BS, Soifer HS, Bowers C, Rossi JJ (2005) siRNA target site secondary structure predictions using local stable substructures. Nucleic Acids Res 33:e30
27. Amarzguioui M, Prydz H (2004) An algorithm for selection of functional siRNA sequences. Biochem Biophys Res Commun 316:1050-1058
28. Gong D, Ferrell JE Jr (2004) Picking a winner: new mechanistic insights into the design of effective siRNAs. Trends Biotechnol 22:451-454
29. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22:326-330
30. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498
31. Bitko V, Barik S (2001) Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol 1:34
32. Bitko V, Musiyenko A, Shulyayeva O, Barik S (2005) Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11:50-55
33. Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME (2004) Lack of interferon response in animals to naked siRNAs. Nat Biotechnol 22:1579-1582
34. Chi JT, Chang HY, Wang NN, Chang DS, Dunphy N, Brown PO (2003) Genomewide view of gene silencing by small interfering RNAs. Proc Natl Acad Sci U S A 100:6343-6346
35. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ (2005) Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 23:222-226
36. Siolas D, Lerner C, Burchard J, Ge W, Linsley PS, Paddison PJ, Hannon GJ, Cleary MA (2005) Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 23:227-231
37. Kim DH, Longo M, Han Y, Lundberg P, Cantin E, Rossi JJ (2004) Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 22:321-325
38. Pebernard S, Iggo RD (2004) Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 72:103-111
39. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell 115:199-208
40. Khvorova A, Reynolds A, Jayasena SD (2003) Functional siRNAs and miRNAs exhibit strand bias. Cell 115:209-216. Erratum in: Cell 115:505
41. Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H (2002) Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res 30:1757-1766
42. Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF (2003) Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem 278:7108-7118
43. Kretschmer-Kazemi Far R, Sczakiel G (2003) The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res 31:4417-4424
44. Luo KQ, Chang DC (2004) The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region. Biochem Biophys Res Commun 318:303-310
45. Judge AD, Sood V, Shaw JR, Fanng D, McClintock K, Maclachlan I (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23:457-462
46. Sledz CA, Holko M, de Veer MJ, Silverman RH, Williams BR (2003) Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5:834-839
47. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21:635-637
48. Persengiev SP, Zhu X, Green MR (2004) Nonspecific, concentration- dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10:12-18
49. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R (2003) Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34:263-264
50. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG, Umayam L, Lee JC, Hughes CM, Shanmugam KS, Bhattacharjee A, Meyerson M, Collins FS (2004) Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A 101:1892-1897
51. Fedorov Y, King A, Anderson E, Karpilow J, Ilsley D, Marshall W, Khvorova A (2005) Different delivery methods-different expression profiles. Nat Methods 2:241
52. Dorsett Y, Tuschl T (2004) siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 3:318-329
53. Manoharan M (2004) RNA interference and chemically modified small interfering RNAs. Curr Opin Chem Biol 8:570-579
54. Chiu YL, Rana TM (2003) siRNA function in RNAi: a chemical modification analysis. RNA 9:1034-1048
55. Czauderna F, Fechtner M, Dames S, Aygun H, Klippel A, Pronk GJ, Giese K, Kaufmann J (2003) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 31:2705-2716
56. Nykanen A, Haley B, Zamore PD (2001) ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107:309-321
57. Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T (2002) Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110:563-574
58. Schwarz DS, Hutvagner G, Haley B, Zamore PD (2002) Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol Cell 10:537-548
59. Hamada M, Ohtsuka T, Kawaida R, Koizumi M, Morita K, Furakawa H, Imanishi T, Miyagishi M, Taira K (2002) Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense Nucleic Acid Drug Dev 12:301-309
60. Harborth J, Elbashir SM, Vandenburgh K, Manninga H, Scaringe SA, Weber K, Tuschl T (2003) Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 13:83-105
61. Amarzguioui M, Holen T, Babaie E, Prydz H (2003) Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 31:589-595
62. Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, Corey DR (2003) RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42:7967-7975
63. Capodici J, Kariko K, Weissman D (2002) Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol 169:5196-5201
64. Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA (2004) In vivo activity of nuclease-resistant siRNAs. RNA 10:766-771
65. Allerson CR, Sioufi N, Jarres R, Prakash TP, Naik N, Berdeja A, Wanders L, Griffey RH, Swayze EE, Bhat B (2005) Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem 48:901-904
66. Parrish S, Fleenor J, Xu S, Mello C, Fire A (2000) Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol Cell 6:1077-1087
67. Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, Wahren B, Liang Z, Orum H, Koch T, Wahlestedt C (2005) Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 33:439-447
68. Dudek P, Picard D (2004) TROD: T7 RNAi Oligo Designer. Nucleic Acids Res 32 (Web Server issue):W121-W123
69. Myers JW, Jones JT, Meyer T, Ferrell JE Jr (2003) Recombinant Dicer efficiently converts large dsRNAs into siRNAs suitable for gene silencing. Nat Biotechnol 21:324-328
70. Smith NA, Singh SP, Wang MB, Stoutjesdijk PA, Green AG, Waterhouse PM (2000) Total silencing by intron-spliced hairpin RNAs. Nature 407:319-320
71. Xia XG, Zhou H, Ding H, Affar el B, Shi Y, Xu Z (2003) An enhanced U6 promoter for synthesis of short hairpin RNA. Nucleic Acids Res 31:e100
72. Czauderna F, Santel A, Hinz M, Fechtner M, Durieux B, Fisch G, Leenders F, Arnold W, Giese K, Klippel A, Kaufmann J (2003) Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res 31:e127
73. Qin XF, An DS, Chen IS, Baltimore D (2003) Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 100:183-188
74. Arts GJ, Langemeijer E, Tissingh R, Ma L, Pavliska H, Dokic K, Dooijes R, Mesic E, Clasen R, Michiels F, van der Schueren J, Lambrecht M, Herman S, Brys R, Thys K, Hoffmann M, Tomme P, van Es H (2003) Adenoviral vectors expressing siRNAs for discovery and validation of gene function. Genome Res 13:2325-2332
75. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Ihrig MM, McManus MT, Gertler FB, Scott ML, Van Parijs L (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 33:401-406. Erratum in: Nat Genet 34:231
76. Wiznerowicz M, Trono D (2003) Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 77:8957-8961
77. Brummelkamp TR, Bernards R, Agami R (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2:243-247
78. Barquinero J, Eixarch H, Perez-Melgosa M (2004) Retroviral vectors: new applications for an old tool. Gene Ther 11(Suppl 1):S3-S9
79. Matsukura S, Jones PA, Takai D (2003) Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res 31:e77
80. Bartosch B, Cosset FL (2004) Strategies for retargeted gene delivery using vectors derived from lentiviruses. Curr Gene Ther 4:427-443
81. Spagnou S, Miller AD, Keller M (2004) Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43:13348-13356
82. Leng Q, Scaria P, Zhu J, Ambulos N, Campbell P, Mixson AJ (2005) Highly branched HK peptides are effective carriers of siRNA. J Gene Med 7:977-986
83. Lorenz C, Hadwiger P, John M, Vornlocher HP, Unverzagt C (2004) Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 14:4975-4977
84. Zhang W, Yang H, Kong X, Mohapatra S, San Juan-Vergara H, Hellermann G, Behera S, Singam R, Lockey RF, Mohapatra SS (2005) Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 11:56-62. Erratum in: Nat Med 11:233
85. Ma Z, Li J, He F, Wilson A, Pitt B, Li S (2005) Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun 330:755-759
86. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH II (2004) Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127:481-496
87. Ill CR, Chiou HC (2005) Gene therapy progress and prospects: recent progress in transgene and RNAi expression cassettes. Gene Ther 12:795-802
88. Verma IM, Weitzman MD (2004) Gene therapy: twenty-first century medicine. Annu Rev Biochem 74:711-738
89. Barik S (2004) Development of gene-specific double-stranded RNA drugs. Ann Med 36:540-551
90. Barik S (2004) Control of nonsegmented negative-strand RNA virus replication by siRNA. Virus Res 102:27-35
91. Shankar P, Manjunath N, Lieberman J (2005) The prospect of silencing disease using RNA interference. JAMA 293:1367-1373
92. Lu PY, Xie FY, Woodle MC (2005) Modulation of angiogenesis with siRNA inhibitors for novel therapeutics. Trends Mol Med 11:104-113
93. Ameyar-Zazoua M, Guasconi V, Ait-Si-Ali S (2005) siRNA as a route to new cancer therapies. Expert Opin Biol Ther 5:221-224
94. Forte A, Cipollaro M, Cascino A, Galderisi U (2005) Small interfering RNAs and antisense oligonucleotides for treatment of neurological diseases. Curr Drug Targets 6:21-29
95. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P, Lieberman J (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9:347-351
96. Schiffelers RM, Xu J, Storm G, Woodle MC, Scaria PV (2005) Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum 52:1314-1318
97. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD (2004) CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64:8604-8612
98. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173-178
99. Nakamura H, Siddiqui SS, Shen X, Malik AB, Pulido JS, Kumar NM, Yue BY (2004) RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. Mol Vis 10:703-711
100. Takabatake Y, Isaka Y, Mizui M, Kawachi H, Shimizu F, Ito T, Hori M, Imai E (2005) Exploring RNA interference as a therapeutic strategy for renal disease. Gene Ther 12:965-973
101. Damm-Welk C, Fuchs U, Wossmann W, Borkhardt A (2003) Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference. Semin Cancer Biol 13:283-292
102. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchenio T, Lozano G, Harel-Bellan A (2002) Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci U S A 99:14849-14854
103. Menendez JA, Lupu R (2005) RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells. Int J Mol Med 15:33-40
104. Mukhopadhyay UK, Senderowicz AM, Ferbeyre G (2005) RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells. Cancer Res 65:2872-2881
105. Miller VM, Gouvion CM, Davidson BL, Paulson HL (2004) Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res 32:661-668
106. Xie Z, Romano DM, Tanzi RE (2005) RNA interference-mediated silencing of X11α and X11β attenuates amyloid β-protein levels via differential effects on β-amyloid precursor protein processing. J Biol Chem 280:15413-15421
107. Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A 102:5820-5825
108. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson BL (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10:816-820
109. Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, Henderson CE, Aebischer P (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 11:423-428
110. Xia XG, Zhou H, Zhou S, Yu Y, Wu R, Xu Z (2005) An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase. J Neurochem 92:362-367
111. Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J, Clotet B, Este JA (2002) Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 16:2385-2390
112. Anderson J, Banerjea A, Planelles V, Akkina R (2003) Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res Hum Retrovir 19:699-706
113. Butticaz C, Ciuffi A, Munoz M, Thomas J, Bridge A, Pebernard S, Iggo R, Meylan P, Telenti A (2003) Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression. Antivir Ther 8:373-377
114. Bitko V, Oldenburg A, Garmon NE, Barik S (2003) Profilin is required for viral morphogenesis, syncytium formation, and cell-specific stress fiber induction by respiratory syncytial virus. BMC Microbiol 3:9
115. Shi H, Chamond N, Tschudi C, Ullu E (2004) Selection and characterization of RNA interference-deficient trypanosomes impaired hi target mRNA degradation. Eukaryot Cell 3:1445-1453
116. Rusconi F, Durand-Dubief M, Bastin P (2005) Functional complementation of RNA interference mutants in trypanosomes. BMC Biotechnol 5:6
117. DaRocha WD, Otsu K, Teixeira SM, Donelson JE (2004) Tests of cytoplasmic RNA interference (RNAi) and construction of a tetracycline-inducible T7 promoter system in Trypanosoma cruzi. Mol Biochem Parasitol 133:175-186
118. Robinson KA, Beverley SM (2003) Improvements in transfection efficiency and tests of RNA interference (RNAi) approaches in the protozoan parasite Leishmania. Mol Biochem Parasitol 128:217-228
119. Ullu E, Tschudi C, Chakraborty T (2004) RNA interference in protozoan parasites. Cell Microbiol 6:509-519
120. Kumar R, Adams B, Oldenburg A, Musiyenko A, Barik S (2002) Characterisation and expression of a PP1 serine/threonine protein phosphatase (PfPP1) from the malaria parasite, Plasmodium falciparum: demonstration of its essential role using RNA interference. Malar J 1:5
121. Kowdley KV (2005) Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 39:S3-S8
122. Weber F, Kochs G, Haller O (2004) Inverse interference: how viruses fight the interferon system. Viral Immunol 17:498-515
123. Basler CF, Garcia-Sastre A (2002) Viruses and the type I interferon antiviral system: induction and evasion. Int Rev Immunol 21:305-337
124. Gotoh B, Komatsu T, Takeuchi K, Yokoo J (2002) Paramyxovirus strategies for evading the interferon response. Rev Med Virol 12:337-357
125. Ramaswamy M, Shi L, Monick MM, Hunninghake GW, Look DC (2004) Specific inhibition of type I interferon signal transduction by respiratory syncytial virus. Am J Respir Cell Mol Biol 30:893-900
126. Spann KM, Tran KC, Collins PL (2005) Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-κB, and proinflammatory cytokines. J Virol 79:5353-5362
127. Voinnet O (2005) Induction and suppression of RNA silencing: insights from viral infections. Nat Rev Genet 6:206-220
128. Ahlquist P (2002) RNA-dependent RNA polymerases, viruses, and RNA silencing. Science 296:1270-1273
129. Chang J, Provost P, Taylor JM (2003) Resistance of human hepatitis delta virus RNAs to dicer activity. J Virol 77:11910-11917
130. Hutvagner G, Simard MJ, Mello CC, Zamore PD (2004) Sequence-specific inhibition of small RNA function. PLoS Biol 2:E98
131. Barik S, Bitko V (2005) Pharmacology and emerging clinical applications of RNA. In: Meyers R (ed) Encyclopedia of molecular cell biology and molecular medicine, vol 10. Wiley-VCH, Weinheim, pp 241-275